Literature DB >> 15226383

The opioid receptor like-1 receptor agonist Ro 64-6198 (1S,3aS-8-2,3,3a,4,5,6-hexahydro-1H-phenalen-1-yl-1-phenyl-1,3,8-triaza-spiro[4.5]decan-4-one) produces a discriminative stimulus in rats distinct from that of a mu, kappa, and delta opioid receptor agonist cue.

Matthew D Recker1, Guy A Higgins.   

Abstract

Male Wistar rats were trained to discriminate either the opioid receptor like (ORL)-1 receptor agonist Ro 64-6198 (1S,3aS-8-2,3,3a,4,5,6-hexahydro-1H-phenalen-1-yl-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one) or morphine from saline using a two-choice, food reinforced, operant procedure. Acquisition of Ro 64-6198 discrimination was relatively slow (mean trials to criterion 113 +/- 6), and a final 4 mg/kg dose (initial training dose 2 mg/kg) was required to establish appropriate stimulus control. In comparison, a separate group of rats attained a morphine (2 mg/kg) discrimination in 44 +/- 4 trials. In tests of substitution, Ro 64-6198 produced a dose-related generalization to its own cue (ED(50) of 1.1 mg/kg i.p.), yet only weakly generalized to the morphine cue (19% at 10 mg/kg i.p.). In contrast, morphine generalized completely to the morphine cue (ED(50) of 0.7 mg/kg s.c.), yet only partially generalized to the Ro 64-6198 cue (40% at 6 mg/kg s.c.). The kappa opioid receptor agonist U50,488 [trans-3,4-dichloro-N-methyl-N(2-[1-pyrrolidinyl]cyclohexyl) benzeneacetamide methanesulfonate] (0.3-6 mg/kg s.c.) and the delta opioid receptor agonist SNC-80 [(+)-4-[(alphaR)-alpha-((2S,5R)-4-allyl-2,5-dimethyl-1-piperazinyl)-3-methoxybenzyl]-N,N-diethylbenzamide] (0.3-6 mg/kg i.p.) failed to evoke significant generalization to either cue. The mu opioid receptor agonists codeine (0.3-20 mg/kg) and buprenorphine (0.01-1 mg/kg) completely generalized to the morphine cue, but only buprenorphine partially generalized to the Ro 64-6198 cue. Naloxone pretreatment completely blocked the morphine cue (ED(50) of 0.005 mg/kg s.c.), yet only weakly attenuated the Ro 64-6198 cue at 0.3 mg/kg. Finally, the selective ORL-1 antagonist J-113397 [1-[(3R,4R)-1-cyclooctylmethyl-3-hydroxymethyl-4-piperidyl]-3-ethyl-1, 3-dihydro-2H-benzimidazol-2-one] completely blocked the Ro 64-6198 cue at a dose (30 mg/kg i.p.) that had no effect against the morphine cue. The present studies demonstrate that rats may be trained to discriminate Ro 64-6198 from saline, and the pharmacological characteristics of this cue are most consistent with ORL-1 receptor activation.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15226383     DOI: 10.1124/jpet.104.071423

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  9 in total

Review 1.  Nociceptin Opioid Receptor (NOP) as a Therapeutic Target: Progress in Translation from Preclinical Research to Clinical Utility.

Authors:  Nurulain T Zaveri
Journal:  J Med Chem       Date:  2016-03-14       Impact factor: 7.446

2.  Further characterization of the prototypical nociceptin/orphanin FQ peptide receptor agonist Ro 64-6198 in rodent models of conflict anxiety and despair.

Authors:  Celia Goeldner; Will Spooren; Jürgen Wichmann; Eric P Prinssen
Journal:  Psychopharmacology (Berl)       Date:  2012-01-18       Impact factor: 4.530

Review 3.  Buprenorphine in cancer pain.

Authors:  Mellar P Davis
Journal:  Support Care Cancer       Date:  2005-07-12       Impact factor: 3.603

4.  The 5-HT2C receptor agonist lorcaserin reduces nicotine self-administration, discrimination, and reinstatement: relationship to feeding behavior and impulse control.

Authors:  Guy A Higgins; Leo B Silenieks; Anne Rossmann; Zoe Rizos; Kevin Noble; Ashlie D Soko; Paul J Fletcher
Journal:  Neuropsychopharmacology       Date:  2011-12-21       Impact factor: 7.853

Review 5.  Treating Chronic Pain: An Overview of Clinical Studies Centered on the Buprenorphine Option.

Authors:  Mellar P Davis; Gavril Pasternak; Bertrand Behm
Journal:  Drugs       Date:  2018-08       Impact factor: 9.546

6.  Characterization of the nociceptin receptor (ORL-1) agonist, Ro64-6198, in tests of anxiety across multiple species.

Authors:  G B Varty; L A Hyde; R A Hodgson; S X Lu; M F McCool; T M Kazdoba; R A Del Vecchio; D H Guthrie; A J Pond; M E Grzelak; X Xu; W A Korfmacher; D Tulshian; E M Parker; G A Higgins
Journal:  Psychopharmacology (Berl)       Date:  2005-09-29       Impact factor: 4.530

7.  Effect of novel nociceptin/orphanin FQ-NOP receptor ligands on ethanol drinking in alcohol-preferring msP rats.

Authors:  D Economidou; A Fedeli; R Martin Fardon; F Weiss; M Massi; R Ciccocioppo
Journal:  Peptides       Date:  2006-12       Impact factor: 3.750

8.  Characterization of the Discriminative Stimulus Effects of a NOP Receptor Agonist Ro 64-6198 in Rhesus Monkeys.

Authors:  Phillip A Saccone; Kathy A Zelenock; Angela M Lindsey; Agnieszka Sulima; Kenner C Rice; Eric P Prinssen; Jürgen Wichmann; James H Woods
Journal:  J Pharmacol Exp Ther       Date:  2016-01-22       Impact factor: 4.030

9.  Buprenorphine and pain treatment in pediatric patients: an update.

Authors:  Erendira Vicencio-Rosas; María Gabriela Pérez-Guillé; Carmen Flores-Pérez; Janett Flores-Pérez; Francisca Trujillo-Jiménez; Juan Luis Chávez-Pacheco
Journal:  J Pain Res       Date:  2018-03-15       Impact factor: 3.133

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.